MAIA

#4039
MAIA Biotechnology, Inc. Common Stock
1.3 1 USD
-0.02%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
1.31
1.32
Jahresspanne
1.16
2.46
Tagesänderung
-1.50%
Monatliche Änderung
-10.27%
6 month change
-12.78%
Jahresänderung
-37.02%
Vorheriger Schlusskurs
1.3 3
Open
1.3 2
Tief
1.3 1
Hoch
1.3 2
Volumen
22
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Quarterly report, Q2 FY2026
MAIA Biotechnology, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
MAIA Biotechnology, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
MAIA Biotechnology, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
MAIA Biotechnology, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
MAIA Biotechnology, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
MAIA Biotechnology, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
MAIA Biotechnology, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
MAIA Biotechnology, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
MAIA Biotechnology, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
MAIA Biotechnology, Inc. current report, Q1 FY2026
8-K

MAIA Biotechnology, Inc. current report, Q1 FY2026

Full document

MAIA Biotechnology, Inc. Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by MAIA Biotechnology, Inc. (MAIA) on March 31, 2026. The Company is a biotechnology firm incorporated in Delaware, with principal executive offices in Chicago, IL. Its common stock trades on the NYSE American under the symbol "MAIA." The Company is classified as an emerging growth company.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a specific corporate event rather than periodic financial results.

Material Changes and Events

Under Item 8.01 (Other Events), the Company reported a significant clinical development milestone. On March 31, 2026, MAIA issued a press release stating that in its ongoing Phase 2 clinical trial for non-small cell lung cancer (NSCLC), overall survival exceeded two years for eight patients.

Guidance, Outlook, and Risks

The filing contains extensive forward-looking statements regarding the Company's research and development programs. Management cautioned that actual results may differ materially from expectations due to various risks, including:

  • The initiation, timing, cost, progress, and results of preclinical and clinical studies.
  • The ability to advance product candidates and successfully complete clinical studies.
  • The timing or likelihood of regulatory filings and approvals.
  • The ability to develop, manufacture, and commercialize product candidates.
  • Market acceptance and the size/growth potential of target markets.
  • The ability to obtain and maintain intellectual property protection.

The Company explicitly stated it undertakes no obligation to publicly update or revise any forward-looking statements except as required by law.

Investor Verification Checklist

  • Verify the full details of the Phase 2 clinical trial results in the attached press release (Exhibit 99.1).
  • Confirm the total number of patients enrolled in the NSCLC trial versus the eight patients cited for the survival milestone.
  • Review the Company's most recent 10-K or 10-Q filings for current cash runway and liquidity status, as this 8-K does not contain financial data.
  • Assess the timeline for potential regulatory filings based on the reported clinical progress.

Nachrichten